Graduate Program in Exercise Science and Sports, University of Rio de Janeiro State, Rio de Janeiro, Brazil.
Laboratory of Physical Activity and Health Promotion, University of Rio de Janeiro State, Rio de Janeiro, Brazil.
PLoS One. 2024 Mar 28;19(3):e0299563. doi: 10.1371/journal.pone.0299563. eCollection 2024.
A plateau in oxygen uptake ([Formula: see text]) during an incremental cardiopulmonary exercise test (CPET) to volitional exhaustion appears less likely to occur in special and clinical populations. Secondary maximal oxygen uptake ([Formula: see text]) criteria have been shown to commonly underestimate the actual [Formula: see text]. The verification phase protocol might determine the occurrence of 'true' [Formula: see text] in these populations. The primary aim of the current study was to systematically review and provide a meta-analysis on the suitability of the verification phase for confirming 'true' [Formula: see text] in special and clinical groups. Secondary aims were to explore the applicability of the verification phase according to specific participant characteristics and investigate which test protocols and procedures minimise the differences between the highest [Formula: see text] values attained in the CPET and verification phase.
Electronic databases (PubMed, Web of Science, SPORTDiscus, Scopus, and EMBASE) were searched using specific search strategies and relevant data were extracted from primary studies. Studies meeting inclusion criteria were systematically reviewed. Meta-analysis techniques were applied to quantify weighted mean differences (standard deviations) in peak [Formula: see text] from a CPET and a verification phase within study groups using random-effects models. Subgroup analyses investigated the differences in [Formula: see text] according to individual characteristics and test protocols. The methodological quality of the included primary studies was assessed using a modified Downs and Black checklist to obtain a level of evidence. Participant-level [Formula: see text] data were analysed according to the threshold criteria reported by the studies or the inherent measurement error of the metabolic analysers and displayed as Bland-Altman plots.
Forty-three studies were included in the systematic review, whilst 30 presented quantitative information for meta-analysis. Within the 30 studies, the highest mean [Formula: see text] values attained in the CPET and verification phase protocols were similar (mean difference = -0.00 [95% confidence intervals, CI = -0.03 to 0.03] L·min-1, p = 0.87; level of evidence, LoE: strong). The specific clinical groups with sufficient primary studies to be meta-analysed showed a similar [Formula: see text] between the CPET and verification phase (p > 0.05, LoE: limited to strong). Across all 30 studies, [Formula: see text] was not affected by differences in test protocols (p > 0.05; LoE: moderate to strong). Only 23 (53.5%) of the 43 reviewed studies reported how many participants achieved a lower, equal, or higher [Formula: see text] value in the verification phase versus the CPET or reported or supplied participant-level [Formula: see text] data for this information to be obtained. The percentage of participants that achieved a lower, equal, or higher [Formula: see text] value in the verification phase was highly variable across studies (e.g. the percentage that achieved a higher [Formula: see text] in the verification phase ranged from 0% to 88.9%).
Group-level verification phase data appear useful for confirming a specific CPET protocol likely elicited [Formula: see text], or a reproducible [Formula: see text], for a given special or clinical group. Participant-level data might be useful for confirming whether specific participants have likely elicited [Formula: see text], or a reproducible [Formula: see text], however, more research reporting participant-level data is required before evidence-based guidelines can be given.
PROSPERO (CRD42021247658) https://www.crd.york.ac.uk/prospero.
在递增心肺运动测试(CPET)至意志衰竭期间,氧摄取量([Formula: see text])的高原似乎不太可能出现在特殊和临床人群中。次级最大摄氧量([Formula: see text])标准通常被证明会低估实际的[Formula: see text]。验证阶段方案可能会确定这些人群中“真实”[Formula: see text]的发生。本研究的主要目的是系统地回顾并提供一个荟萃分析,以验证验证阶段在特殊和临床群体中确认“真实”[Formula: see text]的适用性。次要目的是根据特定参与者特征探讨验证阶段的适用性,并调查哪些测试方案和程序可最大程度地减少 CPET 和验证阶段获得的最高[Formula: see text]值之间的差异。
使用特定的搜索策略在电子数据库(PubMed、Web of Science、SPORTDiscus、Scopus 和 EMBASE)中进行搜索,并从主要研究中提取相关数据。符合纳入标准的研究进行系统综述。使用随机效应模型对研究组内 CPET 和验证阶段的峰值[Formula: see text]的加权均数差异(标准差)进行荟萃分析。亚组分析根据个体特征和测试方案探讨[Formula: see text]的差异。使用改良的 Downs 和 Black 清单评估纳入的主要研究的方法学质量,以获得证据水平。根据研究报告的阈值标准或代谢分析仪的固有测量误差,对参与者水平的[Formula: see text]数据进行分析,并以 Bland-Altman 图显示。
共纳入 43 项系统评价研究,其中 30 项提供了荟萃分析的定量信息。在这 30 项研究中,CPET 和验证阶段方案中获得的最高平均[Formula: see text]值相似(平均差异=-0.00 [95%置信区间,CI=-0.03 至 0.03] L·min-1,p=0.87;证据水平,LoE:强)。具有足够主要研究进行荟萃分析的特定临床群体在 CPET 和验证阶段之间表现出相似的[Formula: see text](p>0.05,LoE:有限到强)。在所有 30 项研究中,[Formula: see text]不受测试方案差异的影响(p>0.05;LoE:中等至强)。只有 23(53.5%)项综述研究报告了在验证阶段有多少参与者获得了低于、等于或高于 CPET 的[Formula: see text]值,或者报告或提供了参与者水平的[Formula: see text]数据以获取此信息。在研究中,达到验证阶段较低、相等或更高[Formula: see text]值的参与者百分比差异很大(例如,在验证阶段达到更高[Formula: see text]值的百分比范围从 0%到 88.9%)。
组水平验证阶段数据似乎可用于确认特定的 CPET 方案可能引发了特定特殊或临床群体的[Formula: see text],或产生了可重现的[Formula: see text]。然而,需要更多报告参与者水平数据的研究,才能给出基于证据的指南。
PROSPERO(CRD42021247658)https://www.crd.york.ac.uk/prospero.